Biomea Fusion (BMEA) Projected to Post Quarterly Earnings on Monday

Biomea Fusion (NASDAQ:BMEA) is projected to announce its earnings results before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($1.00) per share for the quarter.

Biomea Fusion (NASDAQ:BMEA) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.19. On average, analysts expect Biomea Fusion to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Biomea Fusion Trading Up 8.7 %

Shares of BMEA opened at $2.12 on Friday. Biomea Fusion has a 12-month low of $1.86 and a 12-month high of $13.66. The company has a market cap of $79.65 million, a PE ratio of -0.53 and a beta of -0.07. The stock has a 50-day moving average price of $3.10 and a 200-day moving average price of $5.80.

Analyst Ratings Changes

Several brokerages have issued reports on BMEA. Oppenheimer set a $10.00 target price on shares of Biomea Fusion in a research report on Monday, March 24th. D. Boral Capital reiterated a “buy” rating and issued a $16.00 target price on shares of Biomea Fusion in a research report on Wednesday, March 19th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Biomea Fusion in a research note on Monday, March 31st. Finally, Barclays dropped their price target on Biomea Fusion from $11.00 to $3.00 and set an “equal weight” rating for the company in a research note on Wednesday. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $23.91.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.